NO20013408D0 - Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi - Google Patents

Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi

Info

Publication number
NO20013408D0
NO20013408D0 NO20013408A NO20013408A NO20013408D0 NO 20013408 D0 NO20013408 D0 NO 20013408D0 NO 20013408 A NO20013408 A NO 20013408A NO 20013408 A NO20013408 A NO 20013408A NO 20013408 D0 NO20013408 D0 NO 20013408D0
Authority
NO
Norway
Prior art keywords
substituted
derivatives
prophylaxis
therapy
cerebral ischemia
Prior art date
Application number
NO20013408A
Other languages
English (en)
Other versions
NO20013408L (no
Inventor
Gerd Steinler
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Francisco-Javier Garcia-Ladona
Hans Peter Hofmann
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20013408D0 publication Critical patent/NO20013408D0/no
Publication of NO20013408L publication Critical patent/NO20013408L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20013408A 1999-01-11 2001-07-10 Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi NO20013408L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (de) 1999-01-11 1999-01-11 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
PCT/EP1999/010275 WO2000041697A1 (de) 1999-01-11 1999-12-22 Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie

Publications (2)

Publication Number Publication Date
NO20013408D0 true NO20013408D0 (no) 2001-07-10
NO20013408L NO20013408L (no) 2001-08-21

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013408A NO20013408L (no) 1999-01-11 2001-07-10 Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi

Country Status (19)

Country Link
EP (1) EP1140099A1 (no)
JP (1) JP2002534467A (no)
KR (1) KR20010101440A (no)
CN (1) CN1333685A (no)
AR (1) AR029741A1 (no)
AU (1) AU2285100A (no)
BG (1) BG105688A (no)
BR (1) BR9916888A (no)
CA (1) CA2359390A1 (no)
DE (1) DE19900544A1 (no)
HU (1) HUP0200520A3 (no)
IL (1) IL144145A0 (no)
MX (1) MXPA01006966A (no)
NO (1) NO20013408L (no)
PL (1) PL348916A1 (no)
SK (1) SK9682001A3 (no)
TR (1) TR200102009T2 (no)
WO (1) WO2000041697A1 (no)
ZA (1) ZA200105473B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
CA2539479C (en) * 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
AU2008301884B2 (en) * 2007-09-20 2012-12-20 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
MA41168A (fr) 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
JP3036789B2 (ja) * 1990-06-22 2000-04-24 三井化学株式会社 新規な複素環式化合物及び医薬組成物
DE19746612A1 (de) * 1997-10-22 1999-04-29 Basf Ag 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
CA2359390A1 (en) 2000-07-20
IL144145A0 (en) 2002-05-23
PL348916A1 (en) 2002-06-17
EP1140099A1 (de) 2001-10-10
DE19900544A1 (de) 2000-07-13
WO2000041697A1 (de) 2000-07-20
ZA200105473B (en) 2002-10-03
HUP0200520A2 (hu) 2002-07-29
MXPA01006966A (es) 2002-04-10
NO20013408L (no) 2001-08-21
BR9916888A (pt) 2001-11-20
CN1333685A (zh) 2002-01-30
KR20010101440A (ko) 2001-11-14
AU2285100A (en) 2000-08-01
BG105688A (en) 2002-02-28
SK9682001A3 (en) 2002-03-05
AR029741A1 (es) 2003-07-16
JP2002534467A (ja) 2002-10-15
HUP0200520A3 (en) 2003-04-28
TR200102009T2 (tr) 2002-01-21

Similar Documents

Publication Publication Date Title
NO20032801D0 (no) Tiazolderivater for behandling av PPAR relaterte forstyrrelser
NO20052796D0 (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
EE200200442A (et) Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
NO20016149D0 (no) Indol-derivater og deres anvendelse for behandling av osteporose blant andre applikasjoner
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20032636D0 (no) 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
NO20013409D0 (no) Anvendelse av pyrimidin-derivater for forhindring og behandling av cerebral ischemi
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20013408D0 (no) Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20026005L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20013651D0 (no) Anvendelse av fosfororganiske forbindelser for profylaktisk og terapeutisk behandling av infeksjoner
NO972582D0 (no) Anvendelse av teofyllinderivater, for behandling og profylakse av sjokktilstander, nye xantanforbindelser og deres fremstilling
NO20030127L (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO20026029L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20026028D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
AU2002333843A1 (en) Substituted n-(1,4,5,6-tetrahydrocyclopentapyrazol-3-yl) derivatives and the use of the same for the treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application